Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,214 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium.
Uchimoto T, Iwatsuki K, Komura K, Fukuokaya W, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A, Saruta M, Fujimoto S, Minami T, Yamamoto Y, Yamazaki S, Takai T, Sakamoto M, Nakajima Y, Nishimura K, Maenosono R, Tsujino T, Nakamura K, Fukushima T, Nishio K, Yoshikawa Y, Yamamoto S, Iwatani K, Urabe F, Mori K, Yanagisawa T, Tsuduki S, Takahara K, Inamoto T, Fujita K, Kimura T, Ohno Y, Shiroki R, Azuma H. Uchimoto T, et al. Among authors: fujita k. Int J Clin Oncol. 2024 Oct 28. doi: 10.1007/s10147-024-02649-2. Online ahead of print. Int J Clin Oncol. 2024. PMID: 39467994
Can bladder preservation therapy come to the center stage?
Inamoto T, Ibuki N, Komura K, Juri H, Yamamoto K, Yamamoto K, Fujita K, Nonomura N, Narumi Y, Azuma H. Inamoto T, et al. Among authors: fujita k. Int J Urol. 2018 Feb;25(2):134-140. doi: 10.1111/iju.13495. Epub 2017 Nov 23. Int J Urol. 2018. PMID: 29171098 Review.
Higher neutrophil-to-lymphocyte ratio after the first cycle of the first-line chemotherapy is associated with poor cancer specific survival of upper urinary tract carcinoma patients.
Hashimoto M, Fujita K, Nakayama T, Fujimoto S, Hamaguchi M, Nishimoto M, Kikuchi T, Adomi S, Banno E, De Velasco MA, Saito Y, Shimizu N, Mori Y, Minami T, Nozawa M, Nose K, Yoshimura K, Uemura H. Hashimoto M, et al. Among authors: fujita k. Transl Androl Urol. 2021 Jul;10(7):2838-2847. doi: 10.21037/tau-21-185. Transl Androl Urol. 2021. PMID: 34430386 Free PMC article.
Disseminated intravascular coagulation induced by pazopanib following combination therapy of nivolumab plus ipilimumab in a patient with metastatic renal cell carcinoma.
Hashimoto M, Nakayama T, Fujimoto S, Inoguchi S, Nishimoto M, Kikuchi T, Adomi S, Banno E, De Velasco MA, Saito Y, Shimizu N, Mori Y, Minami T, Fujita K, Nozawa M, Nose K, Yoshimura K, Uemura H. Hashimoto M, et al. Among authors: fujita k. Anticancer Drugs. 2022 Jan 1;33(1):e818-e821. doi: 10.1097/CAD.0000000000001230. Anticancer Drugs. 2022. PMID: 34486537
Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer: A Propensity Score-Matched Analysis.
Matsumura N, Fujita K, Nishimoto M, Yamamoto Y, Kuwahara K, Nagai Y, Minami T, Hatanaka Y, Nozawa M, Morimoto Y, Tahara H, Uejima S, Esa A, Hirayama A, Yoshimura K, Uemura H. Matsumura N, et al. Among authors: fujita k. Front Oncol. 2021 Dec 21;11:769068. doi: 10.3389/fonc.2021.769068. eCollection 2021. Front Oncol. 2021. PMID: 34993133 Free PMC article.
Real-world efficacy and safety of nivolumab plus ipilimumab in untreated metastatic renal cell carcinoma, and the impact of previous nephrectomy on clinical outcome: Japanese multi-institutional retrospective study.
Kato T, Fujita K, Minami T, Nagahara A, Hyashi Y, Nakata W, Matsuzaki K, Nakano K, Hatano K, Kawashima A, Imamura R, Takada S, Nishimura K, Tsujihata M, Takao T, Nakai Y, Nakayama M, Nishimura K, Uemura M, Uemura H, Nonomura N. Kato T, et al. Among authors: fujita k. Int J Clin Oncol. 2022 Oct;27(10):1596-1604. doi: 10.1007/s10147-022-02215-8. Epub 2022 Jul 13. Int J Clin Oncol. 2022. PMID: 35831538
5,214 results